Safety and Effectiveness Study of Intravitreal Conbercept Injection for Exudative Circumscribed Choroidal Haemangioma
Overview
- Phase
- Early Phase 1
- Intervention
- conbercept
- Conditions
- Circumscribed Choroidal Haemangioma
- Sponsor
- Sun Yat-sen University
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Best-corrected visual acuity
- Last Updated
- 7 years ago
Overview
Brief Summary
This prospective clinical trial aims to evaluate the safety and effectiveness study of intravitreal conbercept injection for exudative circumscribed choroidal haemangioma.
Detailed Description
This prospective clinical trial aims to evaluate the safety and effectiveness study of intravitreal conbercept injection for exudative circumscribed choroidal haemangioma: (1)To evaluate therapeutic effect (including both anatomical and functional responses to intravitreal conbercept injection) of intravitreal conbercept injectionfor exudative circumscribed choroidal haemangioma; (2)To evaluate the safety (including side effects of the eye as well as side effects of system) of intravitreal conbercept injection for exudative circumscribed choroidal haemangioma.
Investigators
Jin Chen-jin
Professor
Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •patients with circumscribed choroidal haemangioma who was diagnosed using ophthalmoscopy, fluorescein/indocyanine green angiography, and ultrasonography; 2) presence of reduced visual acuity or metamorphopsia; and 3) subretinal fluid involving the fovea.
Exclusion Criteria
- •patients with abnormal liver function test results, liver disease, porphyria, or previous treatment for circumscribed choroidal haemangioma.
Arms & Interventions
treatment group
The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
Intervention: conbercept
Outcomes
Primary Outcomes
Best-corrected visual acuity
Time Frame: half a year
change of best corrected visual acuity
Secondary Outcomes
- Central foveal thickness(half a year)